Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study

Non-alcoholic fatty liver disease (NAFLD), a hepatic manifestation of metabolic syndrome (MetS), is common and accounts for 80% of cases of elevated liver function tests (LFTs). We assessed the long-term effects of multifactorial intervention on LFTs and their association with cardiovascular disease...

Full description

Saved in:
Bibliographic Details
Published in:Archives of medical science 2011-10, Vol.7 (5), p.796-805
Main Authors: Athyros, Vassilios G, Giouleme, Olga, Ganotakis, Emmanouel S, Elisaf, Moses, Tziomalos, Konstantinos, Vassiliadis, Themistoklis, Liberopoulos, Evangelos N, Theocharidou, Eleni, Karagiannis, Asterios, Mikhailidis, Dimitri P
Format: Article
Language:English
Subjects:
Clinical Research
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Non-alcoholic fatty liver disease (NAFLD), a hepatic manifestation of metabolic syndrome (MetS), is common and accounts for 80% of cases of elevated liver function tests (LFTs). We assessed the long-term effects of multifactorial intervention on LFTs and their association with cardiovascular disease (CVD) events in patients with MetS without diabetes mellitus or CVD. This prospective, randomized, open label study included 1,123 patients (aged 45-65 years). Patients received intensive lifestyle intervention and pharmacotherapy: atorvastatin in all patients (low density lipoprotein cholesterol [LDL-C] targets of
ISSN:1734-1922
1896-9151
DOI:10.5114/aoms.2011.25554